Longevity Health (XAGE) and Its Rivals Compared

A head-to-head review of Longevity Health and its competitors in the health industry

Published on Mar. 2, 2026

Got story updates? Submit your updates here. ›

A detailed comparison of Longevity Health (XAGE) and its rivals across key financial metrics like net margins, return on equity, revenue, earnings per share, and valuation. The analysis also looks at the relative volatility of Longevity Health's stock compared to its competitors and the industry.

Why it matters

This analysis provides investors with a comprehensive look at how Longevity Health is performing relative to its peers in the health industry, helping them make more informed decisions about the company's potential as an investment.

The details

The data shows that while Longevity Health's rivals have higher gross revenue, Longevity Health has lower earnings per share and is trading at a lower price-to-earnings ratio, suggesting it may be more affordable than other companies in the industry. Additionally, Longevity Health has a lower beta, indicating its stock price is less volatile than the average of its competitors.

  • The financial data used in this comparison is from March 2, 2026.

The players

Longevity Health

A health company focused on developing treatments to extend human lifespan and healthspan.

Carmell Therapeutics Corporation

A company that develops plasma-based bioactive materials to stimulate tissue repair and growth after injury, disease, and aging.

Got photos? Submit your photos here. ›

The takeaway

This analysis highlights the competitive landscape in the health industry and Longevity Health's positioning relative to its peers. Investors will need to weigh Longevity Health's lower valuation against its rivals' higher revenue and earnings to determine if it represents a compelling investment opportunity.